Overview of Doxiclat

Property	Description
Active ingredient	Doxycycline (usually as the hyclate salt)
Form	Oral Solid Formulation (Capsule or Tablet)
Pharmacological Class	Tetracycline Antibiotic
Common Use	Anti-infective treatment for bacterial infections
Origin	Semi-synthetic

Doxiclat is a prescription-only medicine (POM) whose active ingredient is Doxycycline, a potent member of the Tetracycline antibiotic class used to combat bacterial infections throughout the body. Its fundamental purpose is to serve as an anti-infective treatment by inhibiting bacterial growth, a mechanism that is pharmacologically established.

What Type of Medicine is Doxiclat? (Definition, Class, and Purpose)

Doxiclat is classified as a broad-spectrum antibacterial agent because it is effective against a wide variety of different bacterial species. As a second-generation Tetracycline antibiotic, Doxiclat belongs to a specific pharmacological class defined by its unique chemical structure and mechanism of action against bacterial cells. Doxycycline is used in treating a broad range of bacterial infections. It is utilized within established infectious disease protocols, reflecting its role in systemic anti-infective treatment.

Doxycycline: Composition and Origin

The core component of Doxiclat is the active ingredient Doxycycline, most frequently present as the salt Doxycycline hyclate. Doxycycline is characterized as a semi-synthetic antibiotic, meaning its chemical structure was modified from a naturally occurring tetracycline base to enhance its properties, such as duration of action and absorption. Doxiclat is manufactured as a single-ingredient product, and its oral solid formulation—typically a capsule or tablet—combines the active ingredient with pharmaceutical excipients to create a stable preparation for oral administration. Doxycycline is categorized as an essential medicine, identifying it as a vital resource for managing bacterial infections.

Doxiclat's Action and Physical Form

Doxiclat functions primarily as a bacteriostatic agent, which means it does not actively kill bacteria but instead puts a stop to their ability to multiply and spread. This action is achieved by interfering with the bacteria's vital process of protein synthesis, specifically by binding to the bacterial 30S ribosomal subunit, thus halting the cell's ability to create proteins necessary for multiplication and survival. This specific target site for Doxycycline's activity is the basis for its function. The medicine is consistently presented as an oral formulation, designed for convenient oral administration, allowing the active Doxycycline to be efficiently absorbed and distributed systemically to the site of the infection.

Regulatory References

What side effects are possible with Doxiclat?

Possible Side Effects and Safety Information

Doxiclat (Doxycycline) has an officially documented safety profile, with potential adverse reactions grouped by frequency and the body system affected, as classified in regulatory documents. This information is derived strictly from government sources like the FDA and EMA and does not constitute medical advice or instruction.

Adverse reactions are most commonly reported in the Gastrointestinal System, including nausea, vomiting, and diarrhea. Effects on the Skin are also frequent, notably photosensitivity reactions, which involve an exaggerated sunburn response upon exposure to sunlight or UV light.

Less common but documented effects involve the Nervous System (e.g., headache) and are rarely linked to Benign Intracranial Hypertension (Pseudotumor Cerebri), a serious condition noted in official warnings. Other rare but serious reactions include severe skin syndromes like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and Clostridioides difficile-Associated Diarrhea (CDAD).

Population-Specific Safety Notes: Regulatory labeling states that Doxiclat is contraindicated in persons with known hypersensitivity to any tetracycline. Use during tooth development (in children under 8 years of age and during the last half of pregnancy) may cause permanent tooth discoloration, a critical safety consideration explicitly defined in the official prescribing information. The risk of esophageal damage (oesophagitis/ulceration) is linked to the manner of administration, specifically when taken without sufficient fluid or immediately before lying down, a documented safety pattern.

Overdose and Emergency Response

The official regulatory profile for Doxiclat (Doxycycline) overdose focuses on the documented manifestations and mandatory emergency actions. Exceeding the recommended dosage is officially noted to result in an increased incidence of known side effects, typically involving gastrointestinal discomfort, such as nausea, vomiting, and diarrhea.

Mandatory Emergency Action

Immediate medical attention is officially required if severe clinical markers are observed. Government health guidance mandates that emergency services must be contacted immediately if the individual experiences collapse, a seizure, or develops trouble breathing. Similarly, inability to be awakened is cited as a critical manifestation necessitating urgent medical care. Contact with the Poison Help line is also a specified action in any suspected overdose scenario.

Management and Procedural Notes

The documented approach to Doxiclat overdose management is strictly symptomatic and supportive treatment. Regulatory guidance explicitly confirms that no specific antidote is known to reverse the effects of Doxycycline. Furthermore, official prescribing information explicitly documents that procedural steps such as dialysis are not considered beneficial for treatment, as the process does not significantly alter the drug’s serum half-life. For patients with impaired renal function, official guidance notes that the drug is not expected to accumulate excessively following overdose.

Therapeutic Uses of Doxiclat

Doxiclat (Doxycycline) is applied across domains where additional symptomatic support is needed for susceptible bacterial infections. Its therapeutic relevance is aligned with key symptom domains and conditions it may assist with managing, particularly those presenting with systemic or localized discomfort. This includes applications requiring targeted treatment for skin issues, vector-borne diseases, and certain urogenital infections.

Management of Inflammatory Skin Symptoms

This medication is generally applied across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative processes. It helps address symptom clusters that may become intense or disruptive, such as the painful, deep-seated lesions associated with acne and rosacea. This support helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability when symptoms are more noticeable.

“Doxiclat helps maintain a sense of stability when symptoms are more noticeable, relevant in situations involving recurrent or episodic manifestations.”

Supportive Relief for Acute Systemic Infections

Doxiclat is often used during phases when symptoms become more noticeable in conditions associated with acute or disruptive episodes, including serious vector-borne fevers. It plays a role in managing symptoms that create noticeable physiological strain, such as high fever and malaise. This provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Inflammatory Symptoms
Doxiclat is relevant for easing symptoms related to inflammatory states in skin conditions, supporting relief for symptoms that create noticeable functional strain.

Regulatory References

NIH MedlinePlus overview of Doxycycline

Eligibility and Restrictions for Use

Who Can and Cannot Use Doxiclat?

Eligibility for Doxiclat (Doxycycline) is strictly defined by regulatory authorities based on population characteristics and specific physiological status.

Contraindicated Populations

Use of Doxiclat is absolutely prohibited for the following populations, as stated in official labeling:

Individuals with a known hypersensitivity to Doxycycline or any other tetracycline-class antibiotic.
Pregnant women and nursing/lactating mothers.
Patients diagnosed with severe hepatic function disorders.

Age-Related Eligibility and Restrictions

Age Group	Eligibility Status (Regulatory Wording)
Children under 8 years	Not Recommended/Contraindicated for routine use due to risk of permanent tooth discoloration.
Adults and Adolescents	Approved for standard use.

Use in children under 8 is restricted only to cases of severe or life-threatening infections where the benefits are deemed to outweigh the developmental risks, and no alternative is available. The drug is approved for general use in adults and adolescents.

Condition-Specific Considerations

While use is contraindicated in severe hepatic impairment, patients with renal impairment do not require a dose adjustment, as stated in the prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns between Doxiclat (Doxycycline) and other substances, as reported in government regulatory documents.

Officially Documented Interaction Classifications

Prohibited Combinations

Co-administration with oral retinoids (such as Isotretinoin) is restricted due to a documented increased risk of Intracranial Hypertension. The regulatory label also documents a risk of fatal renal toxicity when Doxiclat is combined with the inhalational anesthetic methoxyflurane.

Interactions Affecting Systemic Exposure

Certain anticonvulsant medicines, including phenytoin, carbamazepine, and barbiturates, are documented to decrease the plasma half-life of Doxiclat, resulting in reduced systemic exposure. This is a pharmacokinetic interaction.

Pharmacodynamic and Timing Interactions

Oral Anticoagulants: Doxiclat is documented to depress plasma prothrombin activity, potentially enhancing the effect of oral anticoagulants like Warfarin. Co-administration with hormonal oral contraceptives may render the contraceptive less effective.
Absorption Interference: Substances containing polyvalent cations, such as antacids (aluminum, calcium, magnesium), iron preparations, bismuth subsalicylate, and oral zinc, impair Doxiclat absorption through chelation. These products must be administered with a mandatory separation of at least two to three hours.
Food: The absorption of Doxiclat is officially documented as not markedly influenced by simultaneous ingestion of food or milk.

Mechanism of Action

Doxiclat operates through a dual mechanistic approach that targets essential bacterial survival processes while simultaneously interfering with common resistance pathways.

Blocking Bacterial Protein Synthesis

This domain covers the primary action of the Doxycycline component, which acts directly on the bacterial 30S ribosomal subunit . By physically binding to this site, the drug prevents bacteria from linking amino acids to create necessary proteins, thereby interfering with bacterial growth and reproduction (bacteriostasis). This action modifies early molecular steps that shape the systemic consequence of reduced bacterial replication.

Neutralizing Bacterial Defense Mechanisms

This domain involves the action of the Clavulanate component, which acts as a suicide inhibitor by permanently deactivating key bacterial defense enzymes, such as beta-lactamases . This neutralization ensures that the primary inhibitory drug (Doxycycline) is not destroyed, thereby maintaining adequate drug concentration at the target site. This mechanism results in the modulation of activity within targeted pathways by inhibiting the biological function of bacterial resistance mechanisms.

Dosage and Administration Information

The use of Doxiclat (doxycycline) is characterized by specific administration guidelines and dosage schedules. The medicine is primarily administered via the oral route (capsules, tablets), with an intravenous (IV) option available for severe cases or when oral intake is not feasible.

Official Dosing and Frequency Regimens

Dosing varies based on the severity of the condition and patient age, following a two-step approach for many uses:

Adult Dosing: Standard dosing protocols include 200 mg on the first day, typically administered as 100 mg every 12 hours, followed by a maintenance dose of 100 mg once daily. For more severe conditions, 100 mg every 12 hours may be maintained throughout the treatment period.
Pediatric Dosing (leq 45 kg): For children aged 8 years and older weighing 45 kg or less, the initial dose is 4.4 mg/kg of body weight (divided into two doses) on day one, followed by 2.2 mg/kg daily for maintenance. Children over 45 kg receive the adult dose.

Administration Conditions and Course Duration

Proper use involves adherence to practical intake instructions to minimize the risk of esophageal irritation:

Fluid and Posture: Oral formulations are taken with a full glass of water (adequate fluid) and the patient remains in an upright position (sitting or standing) for at least 30 minutes after ingestion.
Food Relationship: While some formulations are taken on an empty stomach, Doxiclat may be taken with food or milk if gastric irritation occurs, as its absorption is not markedly influenced.
Duration: Therapy typically continues for 10 days for streptococcal infections and for at least 24 to 48 hours after fever and symptoms have subsided for other acute infections. Specific courses, such as 7 days for uncomplicated Chlamydia infections, are standard for specific conditions.
Renal Impairment: No dose adjustment is necessary for patients with impaired renal function.

Recent Clinical Evidence

Research evidence / Overview of studies for Doxiclat

The following information summarizes the types of clinical research conducted on Doxiclat (Doxycycline), outlining the study designs, the outcomes that were monitored, and what aspects of treatment remain under investigation. Findings described here reflect group patterns observed in studies and do not determine whether an individual will respond similarly.

Evidence for Core Antibacterial Treatment

Doxiclat was evaluated for its use in treating a broad array of infections caused by susceptible pathogens. This area of research relies on a foundation of historical clinical trials, systematic reviews, and accepted clinical experience which details the history of clinical evaluation for the medicine. Studies primarily focused on outcomes such as the measurement of clinical resolution—a measured change in infection signs and symptoms—and the presence of the causative organism.

The research examined populations including adults and older children (typically aged 8 and above) who were diagnosed with acute infections. A key limitation is that many core indications are supported by older clinical trial data; the study landscape may lack large-scale, modern Randomized Controlled Trials (RCTs).

Evidence for Inflammatory Skin Conditions

Dedicated research, including randomized controlled trials (RCTs), was used to evaluate Doxiclat, particularly its specialized formulations, for conditions such as rosacea and severe acne. Studies explored outcomes related to physical discomfort by measuring the change in the count of inflammatory lesions and assessing clinical status using standardized grading scales.

Research highlights changes measured during the study period over intermediate follow-up durations, with trials reporting patterns in the number of inflammatory lesions that were measured when compared to placebo groups. Reported outcomes consistently indicated that the studies did not measure a meaningful effect on the generalized facial redness, or erythema, associated with rosacea. Comparative evidence is lacking for some newer, specialized formulations when measured against all other active treatment options.

Evidence for Prophylactic Use

Research has also examined Doxiclat’s use in scenarios involving disease prevention. This research utilized field clinical trials and controlled studies among populations such as travelers and deployed personnel. The main outcomes monitored were the incidence of new infections over a defined time interval and the patient's adherence to the daily regimen. Evidence suggests patterns related to adherence to the daily dosing schedule are highly relevant to the measured outcomes observed in these prevention settings.

Key Studies & References

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Doxycycline (Supports Evidence in Specific Patient Groups)

Frequently Asked Questions (FAQ)

Common questions about Doxiclat (FAQ)

Q: Why is Doxiclat sometimes used for things other than infections?

Official prescribing information indicates that Doxiclat is approved for certain inflammatory skin conditions, which are uses beyond just treating infections. The drug is described as having properties that help control inflammation in addition to its primary antibiotic action, and studies have focused on these non-antibacterial effects in various clinical settings.

Q: How long does it usually take to notice the effects of Doxiclat?

According to official information, the drug typically starts working to inhibit bacterial growth or reduce inflammation within the first 24 to 48 hours after starting therapy. However, the time it takes for a person to notice a substantial improvement in their symptoms can vary widely depending on the type and severity of the condition being treated.

Q: Can Doxiclat be taken with pain relievers like Tylenol (acetaminophen)?

Regulatory guidance does not report a direct drug-drug interaction between Doxiclat and acetaminophen (a common pain reliever). However, official drug safety information suggests general caution when combining any medicine that potentially affects the liver. Questions about combining medicines should be addressed to a healthcare professional.

Q: Are there any specific vitamins or supplements that interact with Doxiclat?

Official regulatory documents specify that the absorption of Doxiclat may be affected by supplements containing polyvalent cations, such as calcium, iron, magnesium, and zinc. The drug label advises a time separation of at least two to three hours from these supplements to reduce the risk of interference.

Q: Does Doxiclat need to be finished entirely, even if symptoms improve quickly?

Official patient guidelines state that the course of therapy is designed to be continued for the full duration prescribed by the healthcare provider. Continuing the medicine as directed, even when symptoms improve, is documented as an important measure to ensure the infection is fully addressed and to help reduce the development of resistance.

Q: What should I know about Doxiclat and its potential effect on the liver?

The official regulatory label indicates that Doxiclat is contraindicated (prohibited from use) in individuals with existing severe liver function disorders. Official guidelines note that liver function may need to be monitored prior to or during the course of therapy.

Q: What does the term 'tetracycline class' mean in relation to Doxiclat?

Doxiclat belongs to the tetracycline class of medicines. This classification refers to its specific chemical structure and its common mechanism of action. According to official documents, it works by binding to a part of the bacteria's cell machinery called the 30S ribosomal subunit, which prevents the bacteria from making necessary proteins for growth.

Q: How long does Doxiclat typically stay in a person's system after the last intake?

Pharmacokinetic data in the official prescribing information indicates that the elimination half-life of the active ingredient typically ranges from 18 to 22 hours. The half-life is a scientific measurement that describes the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: What happens if I miss a scheduled time to take Doxiclat?

Official patient information often describes a standard procedure for a missed dose. This procedure generally involves taking the dose as soon as it is remembered, unless that time is too close to the next scheduled dose. Regulatory guidelines emphasize the importance of maintaining the prescribed dosing schedule.

Q: Is there a link between Doxiclat and increased risk of yeast infections?

Official regulatory safety information notes the potential for microbial overgrowth as a side effect. Fungal infections, such as a vaginal yeast infection or oral thrush, have been reported as possible adverse reactions.

Q: Can Doxiclat be used for a recurring or chronic issue?

Regulatory indications confirm the medicine is approved for treating both acute infections and certain chronic conditions. This may include specific long-term uses, such as for certain skin conditions or prophylactic (preventative) scenarios, where the duration of use is often several weeks or months.

Q: Is Doxiclat available in different strengths or forms?

According to official dosage information, Doxiclat is manufactured in multiple dosage forms, including capsules, tablets, and an oral suspension. It is also available as an intravenous solution for hospital use. The medicine is supplied in various strengths, such as 20 mg, 50 mg, 75 mg, 100 mg, and higher.

Q: Why do official documents mention taking Doxiclat with a full glass of water?

Official administration instructions for the oral formulation describe taking the medicine with a full glass of water and remaining in an upright position for at least 30 minutes. This precaution is explicitly noted in official safety documents to help minimize the risk of irritation or ulceration of the esophagus, a documented safety consideration.

Q: What is the general duration of use for Doxiclat in treating common conditions?

The required duration of use is determined by the specific condition being treated, as outlined in the official prescribing information. For many common acute infections, treatment courses often range from 7 to 10 days. However, certain specialized conditions or preventative treatments may require significantly longer durations.

Q: Is it okay to drink coffee while taking Doxiclat?

While a specific drug interaction with coffee is generally not listed in official documents, regulatory-associated guidance sometimes mentions minimizing the intake of beverages and foods that can irritate the stomach lining. This relates to the fact that gastrointestinal upset is a commonly reported side effect of Doxiclat.

Q: Does Doxiclat have any known interactions with dairy products?

Official warnings primarily focus on the calcium and other polyvalent cations found in many dairy products, as these may interfere with drug absorption. Regulatory documents describe that substances with a high cation content usually need to be separated by at least two to three hours from the Doxiclat dose.

Q: What kind of general expectations should I have when starting Doxiclat?

General expectations, based on official safety and usage information, relate to common side effects and administration procedures. This includes the possibility of experiencing gastrointestinal upset or sun sensitivity, which are commonly reported side effects. Information also emphasizes adherence to administration procedures, such as taking the drug with adequate fluid.

Q: Are there research studies looking at new ways to use Doxiclat?

Research has a history of evaluating Doxiclat for its antibacterial, anti-inflammatory, and preventative uses. While the core indications are established, medical science often continues to investigate and evaluate medicines like Doxiclat for specialized applications and new formulations to enhance its use within the approved therapeutic areas.

How should Doxiclat be stored and disposed of?

How to Store and Dispose of Doxiclat?

The official storage and disposal requirements for Doxiclat (Doxycycline) are designed to maintain the medicine's integrity and ensure environmental safety. This information is based on authoritative governmental prescribing documents.

Storage Requirements

Doxiclat must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and should not be stored above 25 C. It is mandatory to keep the medication in its original container, which should be tightly closed and designed to be light-resistant. This protects the oral solid formulation from moisture and light, which can compromise its stability. As a critical safety rule, Doxiclat must always be kept out of the sight and reach of children and pets.

Disposal Instructions

Expired or unused Doxiclat must be safely discarded. Disposal must follow official national or local guidelines for pharmaceutical waste. It is a regulatory requirement to avoid environmental release, meaning the product should not be flushed down the toilet or emptied into drains, due to its classification as a potential aquatic hazard.

Doxiclat